Events2Join

PANGEA|HIV 2


PANGEA-HIV 2: Phylogenetics And Networks for ... - PubMed

Combining phylogenetics, phylodynamics and epidemiology will allow PANGEA to highlight where prevention efforts should be focussed to reduce the HIV ...

PANGEA-HIV 2: Phylogenetics And Networks for Generalised ...

The PANGEA (Phylogenetics And Networks for Generalized Epidemics in Africa) consortium has generated over 18 000 NGS HIV sequences from five countries in sub- ...

Who we are - Pangea HIV

PANGEA-HIV 2 (Phylogenetics And Networks for Generalised Epidemics in Africa) is a collaboration between scientists from the Africa Health Research ...

Special Populations: HIV-2 Infection | NIH

HIV-2 infection is endemic in West Africa, with certain countries experiencing a population prevalence of >1%.

Core Concepts - HIV-2 Infection - Key Populations

Most persons infected with HIV-2 reside in West Africa, or in countries that have strong colonial or socioeconomic ties with West Africa.

Tracing the origin and history of the HIV-2 epidemic - PNAS

The temporal setting of interspecies transmissions reveals that the origin of HIV-2 is not as enigmatic as previously suggested (29). Seroprevalence data ...

Welcome — Pangea HIV

PANGEA is a network of African, European and American researchers identifying individual and population-level factors that drive HIV transmission in ...

What Is HIV-2? - Verywell Health

HIV-2 is a viral subtype mainly seen in West Africa. Learn about its origin, transmission, and mortality rates, and how it differs from ...

Differences between HIV-1 and HIV-2 - MedicalNewsToday

Differences between HIV-1 and HIV-2 ... HIV-1 and HIV-2 are both types of HIV. While both weaken the immune system, HIV-2 develops more slowly and has a lower ...

Special Populations: HIV-2 Infection and Pregnancy | NIH

HIV-2 infection is endemic in West African countries, including Burkina Faso, Cape Verde, The Gambia, Ghana, Guinea, Guinea-Bissau, Ivory Coast, Liberia, Mali, ...

1 and HIV-2 Circulating Subtypes: A Systematic Literature Review ...

Globally, circulating recombinant forms (CRFs)/unique recombinant forms (URFs) accounted for 29% of HIV-1 strains, followed by subtype C (23%) and subtype A ( ...

HIV-1 and HIV-2 - Aidsmap

HIV-1 and HIV-2 antigens are distinct enough that if a diagnostic test is developed only to detect HIV-1, it will not reliably detect HIV-2.

HIV-1 versus HIV-2: What's the Difference? - News-Medical

The human immunodeficiency virus is classified into two main types: HIV-1 and HIV-2. HIV-1 was discovered first and is more prevalent worldwide, while HIV-2 ...

Human Immunodeficiency Virus 2 Infection - ScienceDirect.com

HUMAN IMMUNODEFICIENCY VIRUS TYPE 2. HIV-2 was first isolated in the mid-1980s from individuals with acquired immunodeficiency syndrome (AIDS) in West Africa.

ANTIVIRAL ACTIVITY OF LENACAPAVIR AGAINST HIV-2 ISOLATES

Background: Lenacapavir (LEN) is a first-in-class, multistage inhibitor of HIV-1 capsid function in clinical development that was recently approved in the ...

Epidemiology, transmission, natural history, and pathogenesis of ...

Although HIV-1 infection is associated with most of the global AIDS pandemic, HIV-2 is an important cause of infection and disease in ...

Subtypes of HIV - Wikipedia

The subtypes of HIV include two main subtypes, known as HIV type 1 (HIV-1) and HIV type 2 (HIV-2). These subtypes have distinct genetic differences and are ...

HIV-2 Antibody Confirmed Positive Plasma - SeraCare

HIV-2 Antibody Confirmed Positive Plasma 0315-0028 SeraCare Size, Material, Price, Batch #, Donor ID, Analytes, Test Methods, Results, Size / Inventory Status, ...

What Is It with HIV-2? - Physicians' Research Network

Francois Clavel, who first discovered HIV-2, explains how it differs from HIV-1 in pathogenesis and treatment., an article published by the Physicians' ...

HIV data and statistics - World Health Organization (WHO)

... Antiretroviral therapy coverage among people living with HIV (%) (2). 1. More information and data on SDG Target 3.3 Communicable diseases. 2. Triple Billion ...